Section snippets

Main text

Cancers are conventionally classified as “hot” tumors that are associated with high tumor mutation burdens (TMBs) and tumor-infiltrating immune cells or “cold” tumors associated with a dearth of neoantigens and immune cell exclusion.¹ This dichotomy is frequently used to define the degree of pre-existing immune cell reactivity within the tumor microenvironment and has been linked to clinical outcomes including the efficacy of immune checkpoint inhibitor (ICI) treatment.¹ Recently,

Acknowledgments

D.H. is supported by a Cancer Prevention and Research Institute of Texas Early Clinical Investigator Award (RP200549) and the Josephine Hughes Sterling Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work.

Author contributions

D.H. and H.Z. conceived the study. D.H., A.E., and J.X. performed data analyses. D.H., A.S., W.E.-D., E.S.A., S.L.G., M.J.H., H.B., D.S.B.H., S.V.L., P.C.M., R.R.M., T.W.-D., J.M., G.W.S., D.S., and H.Z. contributed to the assembly of the CARIS cohort. D.H. drafted the paper, and all authors participated in the review and editing of the manuscript.

Declaration of interests

A.E., J.X., G.W.S., and D.S. are employees of Caris Life Sciences.S.L.G. serves as a paid consultant/advisor to Pfizer, Daiichi Sankyo, Eli Lilly, AstraZeneca, Genentech, SeaGen, Novartis, and Menarini and has stock ownership in HCA Healthcare.E.S.A. serves as a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Bayer, BMS, Amgen, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis, and Eli Lilly; has received research support (to his

中文翻译：

---

突变负荷和抗 PD-1 结果通常与免疫细胞浸润或淋巴激活相关

 部分片段

 正文

癌症通常被归类为与高肿瘤突变负荷 （TMB） 和肿瘤浸润免疫细胞相关的“热”肿瘤，或与缺乏新抗原和免疫细胞排斥相关的“冷”肿瘤。¹ 这种二分法经常用于定义肿瘤微环境中预先存在的免疫细胞反应性程度，并与临床结果有关，包括免疫检查点抑制剂 （ICI） 治疗的疗效。¹ 最近，

 确认

DH 得到了德克萨斯州癌症预防和研究所早期临床研究者奖 （RP200549） 和 Josephine Hughes Sterling 基金会的支持。资助者在研究设计、数据收集和分析、发表决定或手稿准备方面没有任何作用。作者没有收到这项工作的具体资金。

 作者贡献

D.H. 和 H.Z. 构思了这项研究。D.H.、A.E. 和 J.X. 进行了数据分析。D.H.， A.S.， W.E.-D.， E.S.A.， S.L.G.， M.J.H.， H.B.， D.S.B.H.， S.V.L.， P.C.M.， R.R.M.， T.W.-D.， J.M.， G.W.S.， D.S.， 和 H.Z. 为 CARIS 队列的组装做出了贡献。D.H. 起草了论文，所有作者都参与了手稿的审查和编辑。

 利益申报

A.E.、J.X.、G.W.S. 和 D.S. 是 Caris Life Sciences.S.L.G. 的员工。担任辉瑞、第一三共、礼来、阿斯利康、基因泰克、SeaGen、诺华和美纳里尼的付费顾问/顾问，并拥有 HCA Healthcare.E.S.A. 的股票。担任 Janssen、Astellas、Sanofi、Dendreon、Bayer、BMS、Amgen、Constellation、Blue Earth、Exact Sciences、Invitae、Curium、Pfizer、Merck、AstraZeneca、Clovis 和 Eli Lilly 的付费顾问/顾问;已获得研究支持（到他的